Vir Bio (VIR) Revenue & Revenue Breakdown
Vir Bio Revenue Highlights
Latest Revenue (Y)
$86.18M
Latest Revenue (Q)
$3.08M
Main Segment (Y)
Grant
Vir Bio Revenue by Period
Vir Bio Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $86.18M | -94.55% |
| 2022-12-31 | $1.58B | 45.39% |
| 2021-12-31 | $1.09B | 1516.58% |
| 2020-12-31 | $67.25M | 9357.81% |
| 2019-12-31 | $711.00K | -18.09% |
| 2018-12-31 | $868.00K | 482.55% |
| 2017-12-31 | $149.00K | - |
Vir Bio generated $86.18M in revenue during NA 2023, up -94.55% compared to the previous quarter, and up 9928.57% compared to the same period a year ago.
Vir Bio Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $3.08M | -94.55% |
| 2024-03-31 | $56.38M | 235.83% |
| 2023-12-31 | $16.79M | -509.64% |
| 2023-09-30 | $-4.10M | -67.79% |
| 2023-06-30 | $-12.72M | -127.23% |
| 2023-03-31 | $46.71M | 114.38% |
| 2022-12-31 | $21.79M | -94.13% |
| 2022-09-30 | $371.43M | -970.13% |
| 2022-06-30 | $-42.69M | -103.47% |
| 2022-03-31 | $1.23B | 51.89% |
| 2021-12-31 | $809.76M | 688.37% |
| 2021-09-30 | $102.71M | -40.96% |
| 2021-06-30 | $173.99M | 28658.02% |
| 2021-03-31 | $605.00K | 101.00% |
| 2020-12-31 | $301.00K | 60.11% |
| 2020-09-30 | $188.00K | -99.72% |
| 2020-06-30 | $66.27M | 13507.60% |
| 2020-03-31 | $487.00K | 31.27% |
| 2019-12-31 | $371.00K | 56.54% |
| 2019-09-30 | $237.00K | 175.58% |
| 2019-06-30 | $86.00K | 405.88% |
| 2019-03-31 | $17.00K | 183.33% |
| 2018-12-31 | $6.00K | -94.74% |
| 2018-09-30 | $114.00K | -97.55% |
| 2018-06-30 | $4.66M | - |
Vir Bio generated $3.08M in revenue during Q2 2024, up -94.55% compared to the previous quarter, and up 6.58% compared to the same period a year ago.
Vir Bio Revenue Breakdown
Vir Bio Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| License Revenue | - | - | - | - | - |
| Collaboration Revenue | $37.27M | $1.51B | $917.19M | - | - |
| Contract Revenue | $2.23M | $52.71M | $169.87M | - | - |
| Grant | $46.69M | $900.00K | - | - | - |
| License | - | $22.29M | - | $22.75M | - |
Vir Bio's latest annual revenue breakdown by segment (product or service), as of Dec 23: Grant (54.17%), Collaboration Revenue (43.24%), and Contract Revenue (2.59%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue | $55.00K | - | $-4.39M | $46.57M | $21.61M | $309.14M | $-54.94M | $1.23B | $809.46M | $102.40M | $5.33M | - | - | - | - | - | - | - | - | - |
| Contract Revenue | $886.00K | $52.19M | $744.00K | $289.00K | $1.06M | $138.00K | $180.00K | $40.00M | $12.25M | $282.00K | $293.00K | $315.00K | $605.00K | $237.00K | - | - | - | - | - | - |
| Grant | $2.13M | $5.17M | $23.43M | $6.74M | $16.52M | $200.00K | $609.00K | $1.17M | - | - | - | - | - | - | - | - | - | - | - | - |
| License Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| License | - | - | - | - | - | - | - | $22.29M | - | - | - | - | $22.75M | - | - | - | - | - | - | - |
Vir Bio's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Grant (69.40%), Contract Revenue (28.81%), and Collaboration Revenue (1.79%).
Vir Bio Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| VIR | Vir Bio | $86.18M | $3.08M |
| CVAC | CureVac | $52.70M | $12.37M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| KRTX | Karuna Therapeutics | $654.00K | - |
| VKTX | Viking Therapeutics | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| MDGL | Madrigal Pharmaceuticals | - | $62.17M |
| TERN | Terns Pharmaceuticals | - | - |
| AKRO | Akero Therapeutics | - | - |
VIR Revenue FAQ
What is Vir Bio’s yearly revenue?
Vir Bio's yearly revenue for 2023 was $86.18M, representing a decrease of -94.55% compared to 2022. The company's yearly revenue for 2022 was $1.58B, representing an increase of 45.39% compared to 2021. VIR's yearly revenue for 2021 was $1.09B, representing an increase of 1516.58% compared to 2020.
What is Vir Bio’s quarterly revenue?
Vir Bio's quarterly revenue for Q2 2024 was $3.08M, a -94.55% decrease from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $56.38M, a 235.83% increase from the previous quarter (Q4 2023), and a 20.69% increase year-over-year (Q1 2023). VIR's quarterly revenue for Q4 2023 was $16.79M, a -509.64% decrease from the previous quarter (Q3 2023), and a -22.96% decrease year-over-year (Q4 2022).
What is Vir Bio’s revenue growth rate?
Vir Bio's revenue growth rate for the last 3 years (2021-2023) was -92.07%, and for the last 5 years (2019-2023) was 12020.96%.
What are Vir Bio’s revenue streams?
Vir Bio's revenue streams in c 23 are Collaboration Revenue, Contract Revenue, and Grant. Collaboration Revenue generated $37.27M in revenue, accounting 43.24% of the company's total revenue, down -97.52% year-over-year. Contract Revenue generated $2.23M in revenue, accounting 2.59% of the company's total revenue, down -95.77% year-over-year. Grant generated $46.69M in revenue, accounting 54.17% of the company's total revenue, up 5087.33% year-over-year.
What is Vir Bio’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Vir Bio was Grant. This segment made a revenue of $46.69M, representing 54.17% of the company's total revenue.